Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.,Cellular & Molecular Immunology

当前位置： X-MOL 学术 › Cell. Mol. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Cellular & Molecular Immunology ( IF 21.8 ) Pub Date : 2020-03-19 , DOI: 10.1038/s41423-020-0400-4
Wanbo Tai ₁ , Lei He ₂ , Xiujuan Zhang ₁ , Jing Pu _{1,

3} , Denis Voronin ₁ , Shibo Jiang _{1,

3} , Yusen Zhou ₂ , Lanying Du ₁

Affiliation

The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.

中文翻译：

2019年新型冠状病毒的受体结合结构域（RBD）的表征：对RBD蛋白作为病毒附着抑制剂和疫苗的开发具有重要意义。

2019年冠状病毒病（COVID-19）的爆发对全球公共卫生构成了严重威胁，呼吁开发安全有效的预防措施和疗法来预防其病原体重症急性呼吸综合征冠状病毒2（SARS-CoV- 2），也称为2019年新型冠状病毒（2019-nCoV）。CoV刺突（S）蛋白在病毒附着，融合和进入过程中起着最重要的作用，并作为抗体，进入抑制剂和疫苗开发的目标。在这里，我们确定了SARS-CoV-2 S蛋白中的受体结合域（RBD），发现RBD蛋白与人和蝙蝠血管紧张素转化酶2（ACE2）受体牢固结合。与SARS-CoV RBD相比，SARS-CoV-2 RBD对ACE2受体的结合亲和力高得多，并且可以阻断结合，因此，SARS-CoV-2 RBD和SARS-CoV RBD对表达ACE2的细胞的附着，从而抑制它们感染宿主细胞。SARS-CoV RBD特异性抗体可以与SARS-CoV-2 RBD蛋白发生交叉反应，SARS-CoV RBD诱导的抗血清可以交叉中和SARS-CoV-2，这表明开发基于SARS-CoV RBD的疫苗的潜力用于预防SARS-CoV-2和SARS-CoV感染。

更新日期：2020-04-24

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11